FOLD Q3 2020 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M+38.3% YoY

Gross Profit

$59M87.5% margin

Operating Income

-$53M-78.2% margin

Net Income

-$64M-94.9% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+8.2%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$901M

Total Liabilities

$580M

Stockholders' Equity

$320M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$49M	+38.3%
Gross Profit	$59M	$43M	+36.8%
Operating Income	-$53M	-$57M	+7.9%
Net Income	-$64M	-$62M	-3.6%

Geographic Segments

Non-US

$47M70%

UNITED STATES

$20M30%